Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

FTC wants more in­for­ma­tion on No­vo-Catal­ent deal in an­titrust re­view

The Fed­er­al Trade Com­mis­sion has ex­tend­ed its an­titrust re­view of No­vo Hold­ings’ $16.5 bil­lion pur­chase of Catal­ent by po­ten­tial­ly an­oth­er 30 days as it re­quests …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Senior Associate - Life Science

Alexandria Real Estate Equities

Seattle, WA, USA